comparemela.com
Home
Live Updates
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs : comparemela.com
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte's Flow Electroporation® and ExPERT technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell therapies ROCKVILLE, Md, Jan. 3, 2023 /PRNewswire/
Related Keywords
Doug Doerfler ,
Prnewswire Maxcyte Inc ,
Linkedin ,
Sv Health Investors ,
Catamaran Bio Inc ,
Twitter ,
Nasdaq ,
Flow Electroporation ,
Catamaran Bio ,
Sofinnova Partners ,
Lightstone Ventures ,
Takeda Ventures ,
Astellas Venture Management ,
Maxcyte ,
Signs ,
Strategic ,
Platform ,
License ,
Catamaran ,
Support ,
Fell ,
Therapy ,
Programs ,
comparemela.com © 2020. All Rights Reserved.